IOL Chemicals and Pharmaceuticals stock rose 19% to ₹172.05, marking a 136% gain since April. The rally follows strong Q4FY26 financial results driven by growth in non-Ibuprofen APIs and increased foreign institutional investment.
IOL Chemicals and Pharmaceuticals shares surged 19% during Tuesday's trading session, reaching a five-year high of ₹172.05. This move brings the stock close to its all-time peak of ₹179.68, last touched in August 2020. The rally has been supported by a significant increase in trading volume, with approximately 27.5 million shares changing hands on the NSE and BSE, accounting for nearly 9% of the company's total equity.
The company’s recent performance shows a shift in investor sentiment, with the stock appreciating 136% since April. This movement follows a strong showing in the quarter ending March 2026, where the company recorded its highest-ever quarterly revenue. According to the company's filings, both its pharmaceutical and chemical divisions contributed to this growth, supported by a better mix of products and improved operational efficiency.
Diversification and Growth Strategy
A key focus for IOL Chemicals has been reducing its reliance on Ibuprofen, a product where it holds a strong global market position due to backward integration in raw materials. The company has seen healthy demand for other APIs including Paracetamol and Metformin. To capitalize on this, IOL Chemicals is actively expanding capacity for its non-Ibuprofen portfolio. Management has signaled an expectation for mid-to-high teens revenue growth in the medium term, with plans to expand profit margins through better use of existing manufacturing capacity.
Institutional interest has also shifted. Shareholding data for the June 2026 quarter indicates that foreign institutional investors (FIIs) increased their stake to 4.87%, up from 1.72% in March 2026. Conversely, the stake held by resident individual shareholders declined during the same period to 26.93%.
Ratings and Operational Context
CareEdge Ratings has highlighted that the company’s competitive advantage remains supported by its cost-efficient manufacturing and established regulatory approvals, including those from the USFDA. The company’s operations benefit from a diversified customer base, with exports accounting for 24% of total sales in FY26. Current operations for key products like Ethyl Acetate and Acetic Anhydride are running at healthy capacity utilization levels, which analysts suggest is a positive indicator for revenue stability.
Investors will likely track the commissioning and utilization rates of the new non-Ibuprofen capacity, as these projects are central to the company’s goal of sustained margin expansion. Additionally, the ability of the company to maintain its competitive cost structure amid fluctuating raw material prices will be a key factor for future performance assessments.